Filter by tags: Radiopharmaceutical Russia Clear all tag filters
9 news articles found
Russia's Rosatom has signed agreements relating to developing nuclear medicine centres in Nicaragua and Kazakhstan, and also a memorandum of understanding with Burkina Faso which includes potential nuclear energy projects.
- Source: World Nuclear News
- Date: Wednesday, 27 March 2024
- Original article: world-nuclear-news.org/Articles/Agreements-Burkina-Faso,-Nicaragua-and-Kazakhstan
Rosatom has begun construction of a new plant for the production of medical isotope products at the Karpov Scientific Research Institute of Physics & Chemistry in Obninsk, Kaluga region. The plant will produce a wide range of radiopharmaceuticals including those based on iodine-131, samarium-153, and molybdenum-99 isotopes. It will also develop promising active radiopharmaceuticals based on lutetium-177, actinium-225, radium-223 and other isotopes. Once completed, in 2025, it will be the largest such facility in Europe, Rosatom says. It will operate in accordance with international GMP (good manufacturing practice) standards.
- Source: NEI Magazine
- Date: Friday, 27 January 2023
- Original article: neimagazine.com/news/newsrosatom-begins-construction-of-radiopharmaceuticals-plant-10546229
The aim is to have production lines operating at the plant in Obninsk by 2025, supplying products for the diagnosis and treatment of patients, including a wide range of cancers. Rosatom says it will ensure Russia's sovereignty in the production of radiopharmaceuticals.
- Source: World Nuclear News
- Date: Wednesday, 25 January 2023
- Original article: world-nuclear-news.org/Articles/Construction-starts-for-Russian-medical-isotopes-p
Bolivia / Russia Tests Production Facilities For Radiopharmaceuticals At New Nuclear Research Centre
According to Rosatom, radiopharmaceuticals produced at the site will be used in more than 5,000 medical procedures a year in Bolivia. Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs containing radioactive isotopes. They can be used as diagnostic and therapeutic agents.
Rosatom said commissioning work is continuing at the facility, which will include a water-cooled research reactor with nominal power of up to 200 kW, an experimental gamma-installation, a cyclotron and radiopharmacology complex, engineering facilities and various laboratories.
- Source: Nucnet
- Date: Thursday, 30 December 2021
- Original article: nucnet.org/news/russia-tests-production-facilities-for-radiopharmaceuticals-at-new-nuclear-research-centre-12-3-2021
The nuclear medicine sector is a small part of the wider nuclear industry, but it provides some of the most pioneering technologies in healthcare - and is close to making personalised medicine a reality. Antonis Kalemis, president of Nuclear Medicine Europe and business manager for molecular imaging at Siemens Healthineers, describes how nuclear medicine also tackles the most trenchant condition in modern healthcare: cancer.
- Source: World Nuclear News
- Date: Thursday, 29 July 2021
- Original article: world-nuclear-news.org/Articles/Viewpoint-Nuclear-medicine-is-crucial-for-fighting
Isotop JSC (part of Rusatom Healthcare, Rosatom’s radiation technologies integrator) on 9 June signed a five-year contract with Brazil’s Nuclear and Energy Research Institute (IPEN, part of the National Nuclear Energy Commission, CNEN) to supply medical isotopes lutetium-177 and actinium-225.
- Source: NEI Magazine
- Date: Friday, 11 June 2021
- Original article: neimagazine.com/news/newsrosatom-to-supply-brazil-with-key-medical-isotopes-8810883
Rusatom Healthcare, part of state nuclear corporation Rosatom, will build Russia’s first radiopharmaceutical plant to meet global GMP good manufacturing practice standards. The new production facility will be in Obninsk at the site of LYa Karpov Scientific Research Institute of Physics & Chemistry (NIFKhl) and will produce drugs for targeted cancer therapy. The design of pharmaceutical production will be carried out by the Central Design and Technological Institute. Pre-design work is planned to be completed this year, for commissioning in 2024 production in early 2025.
- Source: NEI Magazine
- Date: Friday, 07 August 2020
- Original article: neimagazine.com/news/newsrussia-to-open-radiopharmaceutical-plant-in-obninsk-8064702
An agency survey conducted among operators of research reactors that produce radioisotopes for radiopharmaceuticals shows that most major actors continue to produce radioisotopes because the production facilities have been defined as essential by the relevant governments.
However, many airlines are no longer operating because of the pandemic and borders are closed, which affects the distribution of medical radioisotopes around the world.
Joao Osso Junior, head of the radioisotope products and radiation technology section at the IAEA, said the agency is working to assess the need for medical radioisotopes because most research and education activities using isotopes have been put on hold and many hospitals have delayed diagnosis applications.
- Source: Nucnet
- Date: Wednesday, 22 April 2020
- Original article: nucnet.org/news/radioisotope-industry-facing-distribution-challenges-says-iaea-4-2-2020
Three recent announcements will help secure future supplies of vital medical radioisotopes. Westinghouse Electric Company and Nordion (Canada) Inc are to work together on technology to produce cobalt-60 in pressurised water reactors (PWRs); Framatome and Kinectrics have launched a new joint venture to produce lutetium-177 in partnership with Bruce Power; and BWXT Technologies' proprietary technetium-99m generators have passed a testing milestone.
- Source: World Nuclear News
- Date: Saturday, 29 February 2020
- Original article: world-nuclear-news.org/Articles/Companies-work-on-securing-medical-isotope-supplie